Data protection Impressum

Biotech

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.

Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong

3 August 2026

AC Immune will receive a USD 4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial of ACI-7104, its immunotherapy for early Parkinson's disease.

AC Immune secures USD 4 million grant to advance its Parkinson’s immunotherapy

6 July 2026

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (June 2026)

29 June 2026

At a recent BioAlps INSIDE event in Fribourg, the Biofactory Competence Center showcased how its bioprocess expertise helps partners across Western Switzerland move from research to production, with collaborations spanning Lausanne start-up Regenosca and the CHUV.

Fribourg’s Biofactory Competence Center turns biotech research into scalable production

23 June 2026

Neuchâtel’ CSEM contributed system integration and bonding expertise to the development of Hamilton's GlucoSense, a sensor that delivers continuous glucose monitoring inside bioreactors used in biologics production.

CSEM helps bring real-time glucose monitoring to bioreactor manufacturing

3 June 2026

A new EY study ranks Switzerland 3rd worldwide for corporate R&D intensity and 6th for total spending, with 14 Swiss companies among the global top 500.

Switzerland ranks 3rd globally for corporate R&D intensity

18 May 2026

The Swiss Biotech Report 2026 reveals record sector revenues and a landmark year for private funding, as talent and international collaboration continue to underpin Switzerland's position at the forefront of global life sciences.

Swiss Biotech Report 2026: talent and tenacity drive record performance

5 May 2026

1 2 3 4 5 … 19